ALNYLAM PHARMACEUTICALS, INC.(ALNY)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
ALNYLAM PHARMACEUTICALS, INC. (ALNY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALNY at 71.4/100 on a 32-signal composite quality model, placing it at rank #183 of 2,961 stocks — the top 10% of the AI-ranked universe. ALNY scores in the top quartile across balance sheet strength (93.1), revenue growth (84.9), profitability (81.9). Shareholder dilution risk is elevated at 16.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ALNYLAM PHARMACEUTICALS, INC. reports quarterly revenue of $1.3B, net income of $164.5M, an operating margin of 17.9%. Top institutional holders of ALNY by reported 13-F value include FMR, Capital World Investors, BlackRock, based on the most recent SEC filings. ALNY trades on the Nasdaq exchange and files with the SEC under CIK 1178670. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALNY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALNYLAM PHARMACEUTICALS, INC. directly from SEC EDGAR.
AI Quality Score
71.4/100
AI Rank
#183
Revenue
$1.3B
Net Income
$164.5M
Operating Margin
17.9%
ALNY key financials by period
ALNYLAM PHARMACEUTICALS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$3.7B
$313.7M
13.5%
FY 2024
10-K
$2.2B
$-278.2M
-7.9%
FY 2023
10-K
$1.8B
$-440.2M
-15.4%
FY 2022
10-K
$1.0B
$-1.1B
-75.7%
FY 2021
10-K
$844.3M
$-852.8M
-83.9%
FY 2020
10-K
$492.9M
$-858.3M
-168.1%
Institutions holding ALNY
Institutional investors reporting a position in ALNYLAM PHARMACEUTICALS, INC. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Total revenue rose 67% to $1.29B as AMVUTTRA reached $1.01B (+106% YoY), producing $164.5M net income versus a $72.2M loss a year ago.
Biggest Revenue Drivers
Net product revenues$1.17B+74% YoY
Growth from AMVUTTRA driven by increased patient demand, mainly in patients with ATTR-CM in the U.S.
Royalty revenue$71.7M+79% YoY
Increased volume and rate of royalties earned from global net sales of Leqvio by Novartis
Biggest Revenue Drivers
Total revenue: $1.29B+67% YoY
Net product revenues$1.17B+74% YoY
Growth from AMVUTTRA driven by increased patient demand, mainly in patients with ATTR-CM in the U.S.
Within Net product revenues
AMVUTTRA$1.01B+106% YoY
U.S. sales of $809.1M, up 124%, following ATTR-CM approval
Total Rare (GIVLAARI & OXLUMO)$141.9M+11% YoY
Growth from an increased number of patients on GIVLAARI and OXLUMO
Royalty revenue$71.7M+79% YoY
Increased volume and rate of royalties earned from global net sales of Leqvio by Novartis
Net revenues from collaborations$47.2M-23% YoY
Lower Regeneron revenue on completed activities and wind-down of the Initial Research Term, partly offset by Roche ZENITH reimbursements
Largest Expense Items
Research and development$413.1M+28% YoY
Increased clinical trial expenses for ZENITH, TRITON-CM and TRITON-PN Phase 3 trials, partly offset by KARDIA wind-down and lower stock-based compensation
Selling, general and administrative$347.9M+8% YoY
Increased marketing investment for the global AMVUTTRA ATTR-CM launch and higher IT infrastructure costs, partly offset by lower stock-based compensation
Cost of goods sold$298.3M+110% YoY
Increased sales of AMVUTTRA and an associated increase in the blended royalty rate payable on AMVUTTRA net sales
Margins: Cost of goods sold rose to 25.4% of net product revenues from 21.1%, on higher AMVUTTRA sales and a higher blended Sanofi royalty rate; management expects that percentage to keep rising in 2026.
Watch Items from the Filing
Sanofi royalty tiers on AMVUTTRA escalate with volume: 25% of global annual net sales from $500.0M to $1.50B and 30% above $1.50B, compressing gross margin as sales scale.
October 2025 subpoena from the U.S. Attorney's Office for Massachusetts seeks documents on government price reporting for AMVUTTRA, ONPATTRO, OXLUMO and GIVLAARI; no loss contingency accrued.
AMVUTTRA is $1.01B of $1.17B net product revenues; ONPATTRO fell 65% to $18.5M, leaving revenue concentrated in one product.
Regeneron collaboration revenue fell 85% to $5.0M as the Initial Research Term expired in May 2026; no additional targets will be added to the collaboration.
If Blackstone Royalties does not receive $1.00 billion of Leqvio royalties by December 31, 2029, its royalty interest rises from 50% to 55% beginning January 1, 2030.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
